Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > H.C. Wainwright Reiterates Buy Rating on Oncolytics Biotech

<< Previous

Bullboard Posts

Next >>

Comment by CMHarring218431on Aug 22, 2024 10:48am

93 Views

Post# 36191746

RE:RE:H.C. Wainwright Reiterates Buy Rating on Oncolytics Biotech

Why doesn't Oncy put out this easy to read, plain English, fine tuned article that explains the objectives concisely. "Their targeted approach to breast and pancreatic cancer is expected to generate significant value in the NEAR TERM." Let's get started on or front by highlighting this analysis.

<< Previous

Bullboard Posts

Next >>

FLYHT and WestJet partner on weather forecasting